Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Joseph L. Chin"'
Autor:
Louis Lacombe, Ming Zheng, Donald M. Gleason, Simon Tchekmedyian, J. Allen Goas, Joseph L. Chin, Peter Venner, Fred Saad, Robin Murray, Jeferson J. Vinholes
Publikováno v:
JNCI Journal of the National Cancer Institute. 96:879-882
In a placebo-controlled randomized clinical trial, zoledronic acid (4 mg via a 15-minute infusion every 3 weeks for 15 months) reduced the incidence of skeletal-related events (SREs) in men with hormone-refractory metastatic prostate cancer. Among 12
Autor:
Joseph L. Chin, Louis Lacombe, Robin Murray, Fred Saad, Simon Tchekmedyian, J. Allen Goas, Bee Chen, Peter Venner, Jeferson J. Vinholes, Donald M. Gleason
Publikováno v:
JNCI Journal of the National Cancer Institute. 94:1458-1468
Background: Bone metastases are a common cause of morbidity in patients with prostate carcinoma. We studied the effect of a new bisphosphonate, zoledronic acid, which blocks bone destruction, on skeletal complications in prostate cancer patients with
Autor:
M. Guillaume Wientjes, Donn C. Young, David L. Pollifrone, Robert A. Badalament, Jill A. Warner, Pieter L. Venema, Brian J. Miles, Jeffrey D. Harbrecht, Seth P. Lerner, Joseph L. Chin, Jessie L.-S. Au
Publikováno v:
JNCI Journal of the National Cancer Institute. 93:597-604
Background Intravesical chemotherapy (i.e., placement of the drug directly in the bladder) with mitomycin C is beneficial for patients with superficial bladder cancer who are at high risk of recurrence, but standard therapy is empirically based and p